

North America Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class (Anti-viral, Anti-Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route Of Administration (Oral, Parenteral, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)

<https://marketpublishers.com/r/N754E704DFD1EN.html>

Date: July 2024

Pages: 100

Price: US\$ 2,485.00 (Single User License)

ID: N754E704DFD1EN

Abstracts

The North America infectious disease therapeutics market was valued at US\$ 46,376.53 million in 2022 and is expected to reach US\$ 65,955.97 million by 2030; it is estimated to register a CAGR of 4.5% from 2022 to 2030.

Rising Prevalence of Infectious Disease Fuels North America Infectious Disease Therapeutics Market

Infectious diseases are caused by viruses, parasites, bacteria, fungi, toxic products, and other infectious agents. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, 36 million were adults, and 1.7 million were children aged 0-14 years. Also, more than half (53%) were girls and women. Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.

According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate. Also, the expenditure on the healthcare system is huge every year. The Centers for Disease Control and Prevention (CDC) reported that HAIs account for ~1.7 million infection cases and 99,000 deaths every year in American hospitals. Therefore, the rising prevalence of infectious diseases across the globe drives the growth of the infectious disease therapeutics market.

North America Infectious Disease Therapeutics Market Overview

The infectious disease therapeutics market in North America is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the global market in 2022. Growing adoption of technological advancements and rising research and development activities are projected to accelerate the growth of the infectious disease therapeutics market. Moreover, large healthcare businesses and the rising demand for advanced therapeutic solutions to treat chronic conditions and viral diseases are propelling the market expansion in this region. The burgeoning demand for antiviral agents due to the growing adoption of antiviral therapies is anticipated to drive the market in the US. Major medicine and biopharmaceutical companies focus on expanding their antiviral agent manufacturing capacities. For instance, Gilead Sciences, Inc., California, received FDA approval for its investigational antiviral-Remdesivir-to treat COVID-19 in May 2020. Additionally, in April 2022, the US Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) of Gilead Sciences for Veklury (remdesivir) for the treatment of pediatric patients above 28 days, weighing at least 3 kg, and are hospitalized for COVID-19 treatment or have mild-to-moderate COVID-19 infection. In September 2021, the Biden-Harris Administration invested US\$ 2.1 billion through the Centers for Disease Control and Prevention (CDC) to improve infection control and prevention activities across the country's public health and healthcare sectors. These factors are anticipated to boost the US infectious disease therapeutics market growth during the forecast period.

North America Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US\$ Million)

North America Infectious Disease Therapeutics Market Segmentation

The North America infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the North America infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the North America infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the North America infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the North America infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the North America infectious disease therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the North America infectious disease therapeutics market.

Contents

1. INTRODUCTION

- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Key Insights

3. RESEARCH METHODOLOGY

- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research

4. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET - KEY MARKET DYNAMICS

- 4.1 North America Infectious Disease Therapeutics Market - Key Market Dynamics
- 4.2 Market Drivers
 - 4.2.1 Rising Prevalence of Infectious Disease
 - 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
- 4.3 Market Restraints
 - 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
- 4.4 Market Opportunities
 - 4.4.1 Growing Opportunities in Developing Nations
 - 4.4.2 Escalating Threat of Antibiotic Resistance
- 4.5 Future Trends
 - 4.5.1 Rising Number of Product Approvals and Launches
- 4.6 Impact of Drivers and Restraints:

5. INFECTIOUS DISEASE THERAPEUTICS MARKET - NORTH AMERICA MARKET ANALYSIS

- 5.1 North America Infectious Disease Therapeutics Market Revenue (US\$ Million), 2022-2030

6. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS - BY DRUG CLASS

6.1 Overview

6.2 Anti-Viral

6.2.1 Overview

6.2.2 Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

6.3 Anti-bacterial

6.3.1 Overview

6.3.2 Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

6.4 Anti-fungal

6.4.1 Overview

6.4.2 Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

6.5 Others

6.5.1 Overview

6.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

7. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS - BY INDICATION

7.1 Overview

7.2 HIV

7.2.1 Overview

7.2.2 HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

7.3 Hepatitis

7.3.1 Overview

7.3.2 Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

7.4 Tuberculosis

7.4.1 Overview

7.4.2 Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

7.5 Influenza

7.5.1 Overview

7.5.2 Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

7.6 HPV

7.6.1 Overview

7.6.2 HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

7.7 Others

7.7.1 Overview

7.7.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

8. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS - BY ROUTE OF ADMINISTRATION

8.1 Overview

8.2 Oral

8.2.1 Overview

8.2.2 Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

8.3 Parenteral

8.3.1 Overview

8.3.2 Parenteral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

8.4 Topical

8.4.1 Overview

8.4.2 Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

8.5 Others

8.5.1 Overview

8.5.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

9. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS - BY DISTRIBUTION CHANNEL

9.1 Overview

9.2 Hospital Pharmacies

9.2.1 Overview

9.2.2 Hospital Pharmacies: North America Infectious Disease Therapeutics Market -

Revenue and Forecast to 2030 (US\$ Million)

9.3 Retail Pharmacies

9.3.1 Overview

9.3.2 Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

9.4 Others

9.4.1 Overview

9.4.2 Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

10. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET - COUNTRY ANALYSIS

10.1 North America Infectious Disease Therapeutics Market Overview

10.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country

10.1.1.1 North America Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country

10.1.1.2 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.2.1 Overview

10.1.1.3 United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.3.1 United States: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.3.2 United States: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.3.3 United States: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.3.4 United States: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.4 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.4.1 Overview

10.1.1.5 Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.5.1 Canada: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.5.2 Canada: Infectious Disease Therapeutics Market Breakdown, by

Indication

10.1.1.5.3 Canada: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.5.4 Canada: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

10.1.1.6 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.6.1 Overview

10.1.1.7 Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

10.1.1.7.1 Mexico: Infectious Disease Therapeutics Market Breakdown, by Drug Class

10.1.1.7.2 Mexico: Infectious Disease Therapeutics Market Breakdown, by Indication

10.1.1.7.3 Mexico: Infectious Disease Therapeutics Market Breakdown, by Route of Administration

10.1.1.7.4 Mexico: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. INFECTIOUS DISEASE THERAPEUTICS MARKET-INDUSTRY LANDSCAPE

11.1 Overview

11.2 Growth Strategies in the Infectious Disease Therapeutics Market

11.3 Inorganic Growth Strategies

11.3.1 Overview

11.4 Organic Growth Strategies

11.4.1 Overview

12. COMPANY PROFILES

12.1 Pfizer Inc

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Gilead Sciences Inc

12.2.1 Key Facts

- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 F. Hoffmann-La Roche Ltd
 - 12.3.1 Key Facts
 - 12.3.2 Business Description
 - 12.3.3 Products and Services
 - 12.3.4 Financial Overview
 - 12.3.5 SWOT Analysis
 - 12.3.6 Key Developments
- 12.4 Shionogi & Co Ltd
 - 12.4.1 Key Facts
 - 12.4.2 Business Description
 - 12.4.3 Products and Services
 - 12.4.4 Financial Overview
 - 12.4.5 SWOT Analysis
 - 12.4.6 Key Developments
- 12.5 Bayer AG
 - 12.5.1 Key Facts
 - 12.5.2 Business Description
 - 12.5.3 Products and Services
 - 12.5.4 Financial Overview
 - 12.5.5 SWOT Analysis
 - 12.5.6 Key Developments
- 12.6 BioCryst Pharmaceuticals Inc
 - 12.6.1 Key Facts
 - 12.6.2 Business Description
 - 12.6.3 Products and Services
 - 12.6.4 Financial Overview
 - 12.6.5 SWOT Analysis
 - 12.6.6 Key Developments
- 12.7 GSK Plc
 - 12.7.1 Key Facts
 - 12.7.2 Business Description
 - 12.7.3 Products and Services
 - 12.7.4 Financial Overview
 - 12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 AbbVie Inc

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6 Key Developments

12.9 Merck & Co Inc

12.9.1 Key Facts

12.9.2 Business Description

12.9.3 Products and Services

12.9.4 Financial Overview

12.9.5 SWOT Analysis

12.9.6 Key Developments

12.10 Astellas Pharma Inc

12.10.1 Key Facts

12.10.2 Business Description

12.10.3 Products and Services

12.10.4 Financial Overview

12.10.5 SWOT Analysis

12.10.6 Key Developments

13. APPENDIX

13.1 About The Insight Partners

List Of Tables

LIST OF TABLES

Table 1. North America Infectious Disease Therapeutics Market Segmentation

Table 2. Diseases and Funding

Table 3. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million) - by Drug Class

Table 4. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million) - by Indication

Table 5. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million) - by Route of Administration

Table 6. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million) - by Distribution Channel

Table 7. North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million) - by Country

Table 8. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million) - by Drug Class

Table 9. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million) - by Indication

Table 10. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million) - by Route of Administration

Table 11. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million) - by Distribution Channel

Table 12. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million) - by Drug Class

Table 13. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million) - by Indication

Table 14. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million) - by Route of Administration

Table 15. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million) - by Distribution Channel

Table 16. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million) - by Drug Class

Table 17. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million) - by Indication

Table 18. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million) - by Route of Administration

Table 19. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to

2030(US\$ Million) - by Distribution Channel

Table 20. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market

Table 21. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

Figure 1. North America Infectious Disease Therapeutics Market Segmentation, by Country

Figure 2. Impact Analysis of Drivers and Restraints

Figure 3. North America Infectious Disease Therapeutics Market Revenue (US\$ Million), 2022-2030

Figure 4. North America Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)

Figure 5. Anti-viral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 6. Anti-bacterial: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 7. Anti-fungal: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 8. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 9. North America Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)

Figure 10. HIV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 11. Hepatitis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 12. Tuberculosis: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 13. Influenza: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 14. HPV: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 15. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 16. North America Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)

Figure 17. Oral: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 18. Parenteral: North America Infectious Disease Therapeutics Market -

Revenue and Forecast to 2030 (US\$ Million)

Figure 19. Topical: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 20. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 21. North America Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)

Figure 22. Hospital Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 23. Retail Pharmacies: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 24. Others: North America Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US\$ Million)

Figure 25. North America Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US\$ Million)

Figure 26. North America Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)

Figure 27. United States: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million)

Figure 28. Canada: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million)

Figure 29. Mexico: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US\$ Million)

Figure 30. Growth Strategies in the Infectious Disease Therapeutics Market

I would like to order

Product name: North America Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class (Anti-viral, Anti-Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route Of Administration (Oral, Parenteral, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)

Product link: <https://marketpublishers.com/r/N754E704DFD1EN.html>

Price: US\$ 2,485.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N754E704DFD1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970